Risk factors analysis of prognosis of adult acute severe myocarditis

Table 3 Comparison between acute nonsevere myocarditis group and acute severe myocarditis survival group

	ANSM group, n = 80	ASM survival group, n = 185	Total, n = 265
Male, n (%)	51 (63.8)	121 (65.4)	172 (64.9)
Age in yr	39 ± 13	40 ± 15	39 ± 14
QRS duration prolonged, n (%)	0	4 (2.2)	4 (1.5)
Low LVEF, n (%)	8 (10.0)	45 (24.3)	53 (0.2)
Left ventricular dilatation, n (%)	5 (6.3)	43 (23.2)	48 (18.1)
cTnI in μg/L	0.12 (0.03, 0.61)	1.66 (0.25, 6.16)	1.19 (0.10, 0.82)
BNP in pg/mL	56 (32, 106)	401 (69, 1072)	78 (41, 437)
SCr in μmol/L	65 (43, 80)	88 (76, 102)	81 (65, 92)
Cardiogenic shock, n (%)	2 (2.5)	33 (17.8)	35 (13.2)
Malignant ventricular arrhythmia, n (%)	5 (6.3)	31 (16.8)	36 (13.6)
Acute renal failure, n (%)	2 (2.5)	33 (17.8)	35 (13.2)
Follow up duration in yr	2.4 ± 1.2	2.7 ± 1.4	2.6 ± 1.3
Re-hospitalization rate, n (%)	2 (7.5)	4 (2.2)	6 (2.3)
Dilated cardiomyopathy, n (%)	4 (5.0)	7 (3.8)	11 (4.2)

ANSM: Acute nonsevere myocarditis; ASM: Acute severe myocarditis; BNP: Brain natriuretic peptide; cTnI: Cardiac troponin I; LVEF: Left ventricular ejection fraction; SCr: Serum creatinine.